


S.-I. Lee<sup>1,2†</sup>, G.-T. Kim<sup>3†</sup>, H.J. Kim<sup>2</sup>, S.-H. Park<sup>4</sup>,  
and E.-C. Kim<sup>2\*</sup>

<sup>1</sup>Department of Dental Hygiene, School of Health Science, Dankook University, Cheonan, Republic of Korea; <sup>2</sup>Department of Oral and Maxillofacial Pathology, School of Dentistry and Research Center for Tooth and Periodontal Regeneration (MRC), Kyung Hee University, Seoul, Republic of Korea; <sup>3</sup>Department of Oral and Maxillofacial Radiology, School of Dentistry, Kyung Hee University, Seoul, Republic of Korea; and <sup>4</sup>Department of Conservative Dentistry, School of Dentistry, Kyung Hee University, Seoul, Republic of Korea; <sup>†</sup>authors contributing equally to this work; \*corresponding author, eckim@khu.ac.kr

*J Dent Res* DOI: 10.1177/0022034514535214

## NOD2 Mediates Odontoblast Differentiation and RANKL Expression

### APPENDIX



**Appendix Figure.** Muramyl dipeptide (MDP) treatment increased NOD2, TLR2, and TLR4 expression during osteoblast/odontoblast differentiation in human dental pulp cells (HDPCs). HDPCs were cultured with MDP (10  $\mu\text{g}/\text{mL}$ ) for 14 days in osteogenic media (OM) with 10 mM  $\beta$ -glycerophosphate,  $10^{-7}$  M dexamethasone, and 50  $\mu\text{g}/\text{mL}$  L-ascorbic acid. The mRNA and protein expression levels were examined by RT-PCR (A) and Western blot analysis (B). Similar data were obtained from 3 independent experiments.

**Appendix Table.** RT-PCR Primer Lists

Genes	Primer Sequence (5'-3')	Annealing Temp. (°C)	Cycle Number	Product Size (bp)
ALP	F : 5'-ACFTFFCTAAFAATFTCATC-3' R : 5'-CTFFTAFFCFATFCCTTA-3'	55	30	475
OPN	F : 5'-CCAAGTAAGTCCAACGAAAG-3' R : 5'-GGTGATGTCCTCGTCTGTA-3'	55	30	347
OCN	F : 5'-CATGAGAGCCCCTCACA-3' R : 5'-AGAGCGACACCCTAGAC-3'	57	30	310
DMP-1	F : 5'-CAGGAGCACAGGAAAAGGAG-3' R : 5'-CTGGTGGTATCTTCCCCCAGGAG-3'	56	36	213
DSPP	F : 5'-AGAAGGACCTGGCCAAAAAT-3' R : 5'-TCTCTCGGCTACTGCTGT-3'	60	35	280
RANKL	F : 5'-CCAGCATCAAATCCAAGT-3' R : 5'-CCCCTTCAGATGATCCTTC-3'	56	35	605
OPG	F : 5'-TGCAGTACGTCAAGCAGGAG -3' R : 5'-TGACCTCTGTGAAAACAGC-3'	60	35	481
M-CSF	F : 5'-ATGACAGACAGGTGGAAGTCCAGTGTAGAGG -3' R : 5'-TCACACAACCTCAGTAGGTTACAGGTGA TGGGC-3'	60	35	437
TNF- $\alpha$	F : 5'-CTCTFFCCCAFFCAFTCAGA-3' R : 5'-GGCGTTTGGGAAGGTTGGAT-3'	60	35	519
IL-1 $\beta$	F : 5'-TGGAGATGACAGTTCAGAAG-3' R : 5'-GTAAGTGGTCCGTTTATGC-3'	60	35	288
IL-6	F : 5'-TAFCCGCCCCACACAGACAG-3' R : 5'-GGCTGGCATTGTGGTTGGG-3'	60	35	408
IL-11	F : 5'-GCAGCGGACAGGGAAGGGTAAA-3' R : 5'-TGTGCGACTCAGCGGGGTCTG-3'	59	32	176
IL-17	F : 5'-CGATGACTCCTGGGAAGACCTC-3' R : 5'-GTGTGGGCTCCCCAGAGCTCTTA-3'	55	25	524
NOD2	F : 5'-CAGAAGGCCGAGCCGCACAA-3' R : 5'-CCAGACACCAGCGGGCACAG-3'	60	35	145
TLR2	F : 5'-GTGGCCAGCAGGTTCAAGATG-3' R : 5'-AGGACTTATCGCAGCTCTCAG-3'	55	641	35
TLR4	F : 5'-AAGTGTCTGAACTCCCTCCAGG-3' R : 5'-ATGGTCTTATTCATCTGACAGGTGATA-3'	55	278	35
$\beta$ -actin	F : 5'-CATGGATGATGATATCGCCGCG-3' R : 5'-ACATGATCTGGGTGATCTTCTCG-3'	55	35	471